SCHEMBL5654468

SCHEMBL5654468

O=C(O)CCc1ccccc1NC(=O)[C@H](CCCNC(=O)OCc1ccccc1Cl)NC(=O)c1cc2ccccc2o1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.64
TP53 P04637 1/20 0.44
SIRT5 Q9NXA8 4/20 0.41
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
HDAC1 Q13547 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC2 Q92769 1/20 0.39
MCHR1 Q99705 1/20 0.39
FOLH1 Q04609 1/20 0.38
PIN1 Q13526 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656112 0.93 PTGER4 (0.56) PTGER4TP53RAB9AMEN1NPC1
SCHEMBL5653761 0.93 PTGER4 (0.74) PTGER4SIRT5RAB9AMEN1NPC1
SCHEMBL5653989 0.86 PTGER4 (0.67) PTGER4SIRT5TAS1R3TAS1R1HDAC1
SCHEMBL5654471 0.84 HIF1A (0.45) PTGER4SIRT5FOLH1KEAP1NFE2L2
SCHEMBL5653748 0.83 HDAC1 (0.48) PTGER4TP53SIRT5RAB9AMEN1
SCHEMBL5653856 0.83 PTGER4 (0.62) PTGER4TP53RAB9AMEN1NPC1
SCHEMBL5654303 0.83 PTGER4 (0.42) PTGER4SIRT5MEN1KMT2AHDAC1
SCHEMBL5651572 0.82 PTGER4 (0.51) PTGER4TP53RAB9AMEN1NPC1
SCHEMBL5652845 0.80 PTGER4 (0.59) PTGER4TP53RAB9AMEN1NPC1
SCHEMBL5654655 0.79 SIRT5 (0.49) PTGER4SIRT5FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 PTGER4 1/4885TP53 3377/4885SIRT5 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.